 Pyridones
"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 2003 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 4 | 7 | | 2014 | 1 | 1 | 2 | | 2015 | 4 | 2 | 6 | | 2016 | 2 | 4 | 6 | | 2017 | 3 | 2 | 5 | | 2018 | 2 | 2 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 3 | 4 | 7 | | 2021 | 4 | 5 | 9 | | 2022 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridones" by people in Profiles.
-
Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM, Kheir F, Khor YH, Knight SL, Raghu G, Wilson KC, Hossain T. Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022 06; 19(6):1030-1039.
-
Moschos SJ, Sandhu S, Lewis KD, Sullivan RJ, Puzanov I, Johnson DB, Henary HA, Wong H, Upreti VV, Long GV, Flaherty KT. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Invest New Drugs. 2022 Oct; 40(5):1051-1065.
-
Nakano TA, Rankin AW, Annam A, Kulungowski AM, McCallen LM, Hill LR, Chatfield KC. Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. J Pediatr. 2022 Sep; 248:81-88.e1.
-
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S, Marzinke MA. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022 05 16; 225(10):1741-1749.
-
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.
-
Pandey S, Hu Y, Bushman LR, Castillo-Mancilla J, Anderson PL, Cooks RG. Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood. Anal Bioanal Chem. 2022 May; 414(11):3387-3395.
-
Jenrette J, Schwarz K, Trujillo T, Ray L. Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population. Am J Emerg Med. 2022 Feb; 52:191-195.
-
Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, Cohen MS, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ, Eshleman SH. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 2021 11 16; 224(9):1581-1592.
-
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 08 12; 385(7):595-608.
-
Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 10; 20(10):2049-2060.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|